

5.60.048

Section:	Prescription Drugs	Effective Date:	January 1, 2023
Subsection:	Central Nervous System Drugs	Original Policy Date:	January 29, 2021
Subject:	Imcivree	Page:	1 of 6

Last Review Date: December 2, 2022

Imcivree

Description

Imcivree (setmelanotide)

Background

Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist with 20-fold less activity at the melanocortin 3 (MC3) and melanocortin 1 (MC1) receptors. MC4 receptors in the brain are involved in regulation of hunger, satiety, and energy expenditure. Imcivree may re-establish MC4 receptor pathway activity in patients with proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS) associated with insufficient activation of the MC4 receptor, reducing hunger and decreasing body mass index (BMI) through decreased caloric intake and increased energy expenditure (1).

Regulatory Status

FDA-approved indications: Imcivree is indicated for chronic weight management in adult patients with a BMI of 30 kg/m² or higher and in pediatric patients 6 years of age and older with a BMI at or above the 95th percentile due to: (1-2)

- Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in *POMC*, *PCSK1*, or *LEPR* genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
- Bardet-Biedl syndrome (BBS)

Limitations of Use:

Section:	Prescription Drugs	Effective Date:	January 1, 2023
Subsection:	Central Nervous System Drugs	Original Policy Date:	January 29, 2021
Subject:	Imcivree	Page:	2 of 6

Imcivree is not indicated for the treatment of patients with the following conditions as Imcivree would not be expected to be effective: (1-2)

- BMI of 30 kg/m² in adults or BMI at or above the 95th percentile in pediatric patients due to suspected POMC, PCSK1, or LEPR deficiency with *POMC*, *PCSK1*, or *LEPR* variants classified as benign or likely benign.
- BMI of 30 kg/m² in adults or BMI at or above the 95th percentile in pediatric patients not related to POMC, PCSK1, or LEPR deficiency or BBS, including high BMI associated with other genetic syndromes and general (polygenic) high BMI.

Select patients for treatment with Imcivree who have genetically confirmed or suspected deficiency of POMC, PCSK1, or LEPR. Treat patients with variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) in the clinical context of the patient (1).

Select patients for treatment with Incivree who have a clinical diagnosis of BBS (1).

Patients should be periodically assessed for response to Imcivree therapy. For patients with POMC, PCKS1, or LEPR deficiency, evaluate decrease in BMI after 12-16 weeks of treatment. For patients with BBS, evaluate decrease in BMI after 1 year of treatment. If a patient has not shown an appropriate decrease in BMI, discontinue Imcivree as it is unlikely that the patient will achieve and sustain clinically meaningful decrease in BMI with continued treatment (1).

Imcivree may cause depression or suicidal ideation. Patients should be monitored for new onset or worsening of depression. Discontinuation of therapy may be considered if patients experience suicidal thoughts or behaviors (1).

The safety and effectiveness of Imcivree in pediatric patients less than 6 years of age have not been established (1).

Related policies

Weight Loss Medications

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Imcivree may be considered **medically necessary** in patients 6 years of age and older if the conditions indicated below are met.

Section:	Prescription Drugs	Effective Date:	January 1, 2023
Subsection:	Central Nervous System Drugs	Original Policy Date:	January 29, 2021
Subject:	Imcivree	Page:	3 of 6

Imcivree may be considered **investigational** in patients less than 6 years of age and for all other indications.

Prior-Approval Requirements

Age 6 years of age or older

Diagnosis

Patient must have **ONE** of the following:

1. POMC, PCSK1, or LEPR deficiency as determined by an FDA-approved test
 - a. Variants in POMC, PCSK1, or LEPR genes are pathogenic, likely pathogenic, **OR** of uncertain significance (VUS)
2. Bardet-Biedl syndrome (BBS)

AND ALL of the following:

1. Patient has the following:
 - a. Age 18+: Body mass index (BMI) \geq 30 kg/m²
 - b. Age 6-17: Body mass index (BMI) \geq 95th percentile for their age
2. Prescriber agrees to monitor patient's BMI
3. Prescriber agrees to monitor for depression and suicidal ideation
4. **NO** dual therapy with another Prior Authorization (PA) medication for weight loss (see Appendix 1)

Prior – Approval *Renewal* Requirements

Age 6 years of age or older

Diagnosis

Patient must have **ONE** of the following:

1. POMC, PCSK1, or LEPR deficiency as determined by an FDA-approved test
2. Bardet-Biedl syndrome (BBS)

Section:	Prescription Drugs	Effective Date:	January 1, 2023
Subsection:	Central Nervous System Drugs	Original Policy Date:	January 29, 2021
Subject:	Imcivree	Page:	4 of 6

AND ALL of the following:

1. Patient has the following:
 - a. Age 18+, must have **ONE** of the following:
 - i. Body mass index (BMI) is <30 kg/m²
 - ii. Patient has lost ≥ 5% of body mass index (BMI) from baseline
 - b. Age 6-17, must have **ONE** of the following:
 - i. Body mass index (BMI) is < 95th percentile for their age
 - ii. Patient has lost ≥ 5% of body mass index (BMI) from baseline
2. Prescriber agrees to monitor patient's BMI
3. Prescriber agrees to monitor for depression and suicidal ideation
4. **NO** dual therapy with another Prior Authorization (PA) medication for weight loss (see Appendix 1)

Policy Guidelines**Pre - PA Allowance**

None

Prior - Approval Limits

Quantity	30 vials per 90 days	
Duration	POMC, PCSK1, or LEPR deficiency	6 months
	BBS	12 months

Prior – Approval *Renewal* Limits

Quantity	30 vials per 90 days	
Duration	POMC, PCSK1, LEPR deficiency, or BBS	12 months

Rationale**Summary**

Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist. MC4 receptors in the brain are involved in regulation of hunger, satiety, and energy expenditure. Imcivree may re-establish MC4 receptor pathway activity in patients with POMC, PCSK1, or LEPR deficiency, or BBS,

Section:	Prescription Drugs	Effective Date:	January 1, 2023
Subsection:	Central Nervous System Drugs	Original Policy Date:	January 29, 2021
Subject:	Imcivree	Page:	5 of 6

thereby reducing hunger and decreasing body mass index (BMI) through decreased caloric intake and increased energy expenditure. Imcivree may cause depression or suicidal ideation (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Imcivree while maintaining optimal therapeutic outcomes.

References

1. Imcivree [package insert]. Boston, MA: Rhythm Pharmaceuticals, Inc.; June 2022.
2. Centers for Disease Control and Prevention. About Adult BMI. Retrieved from: https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html.

Policy History

Date	Action
January 2021	Addition to PA
March 2021	Annual review
June 2022	Annual review and reference update
July 2022	Per PI update, addition of diagnosis of Bardet-Biedl syndrome (BBS). Also added requirement for an FDA-approved test to POMC, PCSK1, or LEPR deficiency indication
September 2022	Annual review
December 2022	Annual review. Addition of requirement “no dual therapy with another PA medication for weight loss.” Addition of Appendix 1

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 2, 2022 and is effective on January 1, 2023.

Section: Prescription Drugs **Effective Date:** January 1, 2023
Subsection: Central Nervous System Drugs **Original Policy Date:** January 29, 2021
Subject: Imcivree **Page:** 6 of 6

Appendix 1 - List of PA Weight Loss Medications

Generic Name	Brand Name
benzphetamine	N/A
carboxymethylcellulose-cellulose-citric acid	Plenity
diethylpropion	N/A
liraglutide	Saxenda
naltrexone/bupropion	Contrave
orlistat	Xenical
phendimetrazine	N/A
phentermine	Adipxex-P/Lomaira
phentermine/topiramate ER	Qsymia
semaglutide	Wegovy
setmelanotide	Imcivree